42
Participants
Start Date
January 26, 2018
Primary Completion Date
February 14, 2020
Study Completion Date
February 14, 2020
Intranasal oxytocin
Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a oxytocin nasal spray 40 International Units (IU) to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
Intranasal placebo
Each Veteran with a stimulant use disorder, receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
San Francisco VA Medical Center, San Francisco, CA, San Francisco
VA Northern California Health Care System, Mather, CA, Sacramento
VA Portland Health Care System, Portland, OR, Portland
VA Office of Research and Development
FED